An open-label randomized, controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-beta-1a and hydroxychloroquine in hospitalized patients with COVID-19 - Final results from the DisCoVeRy trial
Ader et al., medRxiv, doi:10.1101/2022.02.16.22271064
https://c19hcq.org/discovery.html